Abstract | INTRODUCTION: AREAS COVERED: This article reviews the molecular basis, preclinical and clinical evidence on the safety and efficacy of ipilimumab in prostate cancer. Medical literature search using MEDLINE and online abstracts database of national meetings form the basis of this article. EXPERT OPINION:
|
Authors | Nishith Singh, Ravi A Madan, James L Gulley |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 13
Issue 2
Pg. 303-13
(Feb 2013)
ISSN: 1744-7682 [Electronic] England |
PMID | 23265575
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- CTLA-4 Antigen
- Ipilimumab
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- CTLA-4 Antigen
(immunology)
- Combined Modality Therapy
- Drug Evaluation, Preclinical
- Humans
- Ipilimumab
- Male
- Prostatic Neoplasms
(drug therapy, radiotherapy)
- T-Lymphocytes, Cytotoxic
(immunology)
|